Xeris Biopharma Holdings, Inc. Common Stock (XERS) Stock
NASDAQ · XERS
9.58
Fundamentals
Market cap
$1.66B
Price / Earnings ratio
-95.1x
Price / Sales ratio
4.9x
Price / Book ratio
-167.6x
Return on assets
3.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
NeutralXERSSeptember 9, 2026
Business WireNeutral
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
XERS

Business Wire
Xeris Announces Details for XP-8121 Program Overview Webinar
NeutralXERSAugust 26, 2026
Business WireNeutral
Xeris Announces Details for XP-8121 Program Overview Webinar
XERS

MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights
NeutralXERSAugust 7, 2026
MarketBeatNeutral
Xeris Biopharma Q2 Earnings Call Highlights
XERS

Zacks Investment Research
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
NeutralXERSAugust 6, 2026
Zacks Investment ResearchNeutral
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
XERS
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
350M231M116M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
460M304M152M0
Revenue to Profit
2025$291.8M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$554000.0
Net incomeEarnings
EPS forecast
Actual EPS
$0.01
Q1FY26
The market is expecting earnings per share of $0.01 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
NeutralXERSSeptember 9, 2026
Business WireNeutral
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
XERS

Business Wire
Xeris Announces Details for XP-8121 Program Overview Webinar
NeutralXERSAugust 26, 2026
Business WireNeutral
Xeris Announces Details for XP-8121 Program Overview Webinar
XERS

MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights
NeutralXERSAugust 7, 2026
MarketBeatNeutral
Xeris Biopharma Q2 Earnings Call Highlights
XERS

Zacks Investment Research
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
NeutralXERSAugust 6, 2026
Zacks Investment ResearchNeutral
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
XERS

Business Wire
Xeris Biopharma Reports Second Quarter 2026 Financial Results
NeutralXERSAugust 6, 2026
Business WireNeutral
Xeris Biopharma Reports Second Quarter 2026 Financial Results
XERS

Business Wire
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
NeutralXERSJuly 23, 2026
Business WireNeutral
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
XERS

Zacks Investment Research
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
NeutralXERSJuly 8, 2026
Zacks Investment ResearchNeutral
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
XERS

Business Wire
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NeutralXERSJuly 3, 2026
Business WireNeutral
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
XERS

Business Wire
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NeutralXERSJuly 2, 2026
Business WireNeutral
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
XERS

Business Wire
Xeris Announces Updates to Its Board of Directors
NeutralXERSJune 30, 2026
Business WireNeutral
Xeris Announces Updates to Its Board of Directors
XERS
About Xeris Biopharma Holdings, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees435
CEOMr. John P. Shannon
IPO DateJun 21, 2018
HeadquartersChicago, IL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John P. Shannon | Chairman & CEO | 1962 |
| Mr. Kevin McCulloch | President & COO | 1964 |
| Mr. Steven M. Pieper | Chief Financial Officer | 1977 |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 1964 |
| Dr. Anh T. Nguyen M.B.A., M.D. | Chief Medical Officer | 1975 |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | — |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | — |
| Ms. Kendal Korte | Senior Vice President of Human Resources | — |
Fundamentals
Valuation
Market cap$1.66B
Price-to-sales ratio4.87
Price-to-book value-167.64
Price-earnings ratio-95.10
Return on Equity735.00%
Return on Sales13.00%
Return on Assets3.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.10
Income Statement
Average volume1,839,237
EBITDA$53.43M
1 year high (52w)$10.08
1 year low (52w)$5.25
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$14.00
Est return
53.68%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.4 | -24.7 | +6.1 | +50.3 | ||||||||
| 2022 | -24.9 | +11.7 | +7.6 | -5.4 | -10.2 | -29.0 | -5.3 | +10.6 | -9.3 | +2.6 | -5.7 | -14.2 |
| 2023 | +10.7 | +13.1 | +14.8 | +24.2 | +4.9 | +0.0 | +2.4 | -15.6 | -21.5 | +4.6 | -0.5 | +24.3 |
| 2024 | +8.4 | +22.7 | -30.5 | -18.2 | +29.1 | -8.2 | +14.3 | +15.6 | +10.0 | +15.4 | +1.5 | +0.3 |
| 2025 | +2.9 | +6.7 | +48.8 | -10.0 | +10.3 | -7.5 | +9.2 | +45.5 | +2.8 | +21.1 | -27.5 | +12.8 |
| 2026 | +0.1 | -16.8 | -3.7 | +1.5 | -1.9 | +30.5 | +1.0 | +3.8 | +7.9 |



